STAR · NSE
Strides Pharma Science Limited
₹1,219.8
+1.63% (+₹19.6)
Prev. close
₹1,200.2
Volume
2,82,913
Delivery %
43.5%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Strides Pharma Science Limited
Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasal sprays, topical formulations, and controlled substances; and therapeutic products, including antivirals, antibiotics, NSAIDs, and allergy treatment. It also provides branded generics, prescription medicines, and over-the-counter products for infectious diseases, pain management, cardiology, and wellness; and prescription generics for anti-infectives, CNS, cardiovascular, gastroenterology, pain management, and specialty products. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Badree Komandur
Headquarters
Bengaluru
Employees
3,535
Website
strides.comExchange
View on NSE ↗Key stats
Market cap
₹11,106.81 Cr
P/E ratio (TTM)
17.9
Dividend yield
0.42%
EPS (TTM)
₹67.45
Beta (1Y · daily vs NIFTY 50)
0.62
Beta (5Y · monthly vs NIFTY 50)
1.20
Shares float
5.67 Cr
EPS · quarter ended Jun 2026
₹17.02
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,315.87 Cr | ₹3,070.25 Cr | ₹3,688.39 Cr | ₹4,051.12 Cr | ₹4,565.34 Cr | ₹4,858.68 Cr | |
| EBITDA | ₹729.61 Cr | ₹-131.94 Cr | ₹174.64 Cr | ₹344.40 Cr | ₹886.61 Cr | ₹1,049.16 Cr |
| ₹268.44 Cr | ₹-460.21 Cr | ₹-202.64 Cr | ₹-70.61 Cr | ₹3,593.46 Cr | ₹556.19 Cr | |
| Diluted EPS | ₹29.92 | ₹-51.28 | ₹-22.49 | ₹-7.77 | ₹390.5 | ₹60.34 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹6,638.42 Cr | ₹5,839.76 Cr | ₹6,048.73 Cr | ₹6,927.23 Cr | |
| — | — | ₹3,029.57 Cr | ₹2,516.87 Cr | ₹1,879.63 Cr | ₹1,757.98 Cr | |
| Stockholders' equity | — | — | ₹2,212.26 Cr | ₹2,125.56 Cr | ₹2,551.83 Cr | ₹3,107.57 Cr |
Total assets, Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹481.44 Cr | ₹-257.82 Cr | ₹44.41 Cr | ₹701.07 Cr | ₹684.37 Cr | ₹702.52 Cr | |
| Investing cash flow | ₹-520.82 Cr | ₹-118.73 Cr | ₹302.47 Cr | ₹-150.25 Cr | ₹-89.69 Cr | ₹-173.04 Cr |
| ₹-15.80 Cr | ₹421.32 Cr | ₹-213.92 Cr | ₹-693.32 Cr | ₹-642.58 Cr | ₹-453.41 Cr | |
| Capital expenditure | ₹-297.48 Cr | ₹-143.38 Cr | ₹-94.94 Cr | ₹-118.15 Cr | ₹-247.50 Cr | ₹-417.94 Cr |
| End cash position | ₹125.83 Cr | ₹170.73 Cr | ₹303.50 Cr | ₹161.02 Cr | ₹112.56 Cr | ₹188.70 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 21(2Q) | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25–Jun 25(2Q) | Sep 25–Dec 25(2Q) | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 29.60% | 30.60% | 30.37% | 31.07% | 30.89% | 28.27% | 28.07% | 27.78% | 27.39% | 25.88% | 25.86% | 25.84% | 26.82% | 28.30% | 27.86% | 27.91% |
| Public | 70.40% | 69.40% | 69.63% | 68.93% | 69.11% | 71.73% | 71.93% | 72.22% | 72.61% | 74.12% | 74.14% | 74.16% | 73.18% | 71.70% | 72.14% | 72.09% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Strides Pharma Science Limited | ₹11,106.81 Cr | ₹1,219.8 | 17.9 | 3.57 | 17.9% | 0.57 | +5.4% | +39.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 26
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
10 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.